Wouter Latour, MD, MBA
Chief Executive Officer and Director
Dr. Latour has served as our Chief Executive Officer since September 2011 and has served as a member of our board of directors since October 2011. From June 2011 to September 2011, Dr. Latour served as our Chief Operating Officer. From January 2005 to May 2009, Dr. Latour was Chief Executive Officer and a member of the board of directors of Trinity Biosystems, Inc., a biopharmaceutical company. Prior to these roles, Dr. Latour held numerous executive positions at various pharmaceutical and biotechnology companies. Dr. Latour received an M.D. from the University of Amsterdam and his M.B.A. from Stanford University.
Sean Tucker, PhD
Founder, Chief Scientific Officer and Director
Dr. Tucker’s has served as our Chief Scientific Officer since February 2010 and as a member of our board of directors since March 2004. From March 2004 to February 2010, Dr. Tucker served as our Vice President of Research and Director of Immunology. Prior to this, Dr. Tucker numerous scientific and engineering roles at various biotechnology companies. Dr. Tucker received a B.S. in chemical engineering from the University of Washington, an M.S. in chemical engineering from the University of California, Berkeley and a Ph.D. in immunology from the University of Washington.
David Liebowitz, MD, PhD
Chief Medical Officer
Dr. Liebowitz has served as our Chief Medical Officer since January 2012. From 2007 to 2013, Dr. Liebowitz was Chief Scientific and Medical Officer at Vivaldi Biosciences, Inc. a biosciences company focused on the development of influenza vaccines. Prior to these roles, Dr. Liebowitz held numerous senior scientific roles at various biopharmaceutical companies and was an Assistant Professor at the University of Pennsylvania and the University of Chicago. Dr. Liebowitz received a B.S. and M.S. degree in biology from Emory University, and a M.D. and Ph.D. in molecular genetics and cell biology from the University of Chicago.
John Harland, MBA
Chief Financial Officer
Mr. Harland has served as our Chief Financial Officer since March 2014. From June 2011 to March 2014, Mr. Harland served as Chief Financial Officer and Secretary of Wafergen Biosystems, Inc., a life sciences company focused on molecular biomarkers. From 2008 to 2010, Mr. Harland was Vice President of Finance and Administration and Assistant Secretary at Trinity Biosystems, Inc., a company focusing on oral delivery biopharmaceuticals. Mr. Harland began his career at Arthur Young & Company and is a certified public accountant (inactive) and holds FCA credentials. Mr. Harland received an M.A. in business studies and natural sciences from Cambridge University and his M.B.A. in taxation and finance at Golden Gate University.
Vice President of Manufacturing
Mr. Ingamells has served as our Vice President Manufacturing since May 2015. He has 30 years of experience in the biotechnology industry, including recent roles as Vice President of Manufacturing at Optimer Pharmaceuticals (now Cubist/Merck), and Vice President of Manufacturing Operations at Molecular Medicine Bioservices (now SAFC). Previously, Mr. Ingamells held positions at BioMarin Pharmaceuticals, IDEC (now Biogen), and Genentech, with responsibilities including manufacturing, process development, engineering, facilities, validation, and materials management, where he focused on the development and manufacturing of clinical and commercial enzymes, antibodies, antibiotics, and viral vectors. Mr. Ingamells holds a B.S. in Biochemistry from San Francisco State University.
Senior Vice President Corporate Development & Strategy
Mr. Singh has served as our Senior Vice President Corporate Development & Strategy since January 2016. Most recently, he was a business development consultant at venture-backed Principia Biopharma. Previously at Pharming Group NV, Mr. Singh held senior business development roles and was responsible for the company’s U.S. operations, including fundraising, investor and public relations, clinical development, research and development, manufacturing and government relations. Prior to Pharming, he held management and consulting positions at various biotechnology companies, including at Hyseq Inc. (previously Nuvelo Inc., now ARCA biopharma, Inc.), Bio-Rad Laboratories Inc., and Millipore Corporation. Mr. Singh received his B.A. from Williams College, M.S. from Stanford University and M.B.A. from New York University Stern School of Business, LSE and HEC Paris.